KOSDAQElectrical Equipment336570

Won Tech

₩3,350▲ 3.88%2026-11-18 close
Market Cap
₩299.1B
Turnover
₩800M
Volume
250K
Shares out.
89.3M
PER
10.9×
PBR
1.9×
EPS
₩328
Dividend Yield
1.40%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩50 per share · Prices as of the 2026-11-18 close

01

Report overview

Overseas Mix at 75%, but Q3 2026 Turns to a Parent Net Loss

WON Tech's overseas share has risen to about 75%, but operating profit fell for three straight quarters through Q3 2026 and the company swung to a net loss attributable to controlling shareholders, putting its profitability trend in focus.

  1. 1

    Revenue for 2025 reached KRW 156.8 billion, up 36.1% year on year, and operating profit reached KRW 51.7 billion, up 48.6%, which the company described as its best annual result since its founding.

  2. 2

    Operating profit fell from KRW 11.2 billion in Q1 2026 to KRW 11.1 billion in Q2 and KRW 5.51 billion in Q3, with higher selling, general and administrative expenses and advertising costs cited as the main drivers.

  3. 3

    Net income attributable to controlling shareholders was KRW 10.4 billion in Q1 2026 and KRW 15.4 billion in Q2, then swung to a KRW 2.85 billion net loss in Q3, which the company attributed to foreign currency translation losses that involve no cash outflow.

  4. 4

    The export share rose from 70.0% in 2025 to a cumulative 75.4% for January through September 2026, with the United States and Thailand posting the fastest growth.

  5. 5

    In May 2026 the board approved a KRW 75 billion unsecured private convertible bond issue, and in November it approved cancelling 1,153,767 treasury shares.

02

Business structure

WON Tech makes laser and energy-based medical solutions, and most of its revenue comes from its skin aesthetic medical device segment. In Q1 2026 that segment generated KRW 39.2 billion of the KRW 40.2 billion total, or 97.5%, according to company-released figures.

By product, Oligio series equipment accounted for KRW 19.8 billion, laser equipment such as Picocare, Lavieen and Sandro Dual for KRW 12.0 billion, and consumable tips for KRW 7.4 billion.

The Oligio line is a noninvasive lifting device using RF energy, and its consumable sales following equipment placements are described as the core of its earnings base. Exports reached KRW 31.2 billion in Q1 2026, or 77.5% of revenue, and the 2025 export share was 70.0%.

Overseas operations are organized across four corporate subsidiaries in the United States, Japan, Thailand and China, and press reports said the Thailand unit grew 130.2% in 2025 to KRW 37.2 billion.

Regulatory approvals rest on the US FDA and EU CE marks, and 2026 brought further product approval news from Canada, Vietnam, Mexico and Taiwan.

At CES 2026 in January the company unveiled a noncontact vital-sign measurement solution and a combined laser and electrical stimulation pain therapy device, extending its scope toward healthcare.

The competitive field is the domestic energy-based aesthetic device market, particularly RF lifting, and the Korea Exchange named WON Tech a new 2026 KOSDAQ Rising Star, citing that position.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩33.2B₩7.6B22.9%
2025Q4₩46.4B₩12.2B26.4%
2026Q1₩40.2B₩11.2B27.8%
2026Q2₩47.5B₩11.1B23.3%
2026Q3₩36.2B₩5.5B15.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩81.5B₩26.8B₩13.4B32.8%23.5%29.3%
2023₩115.6B₩46B₩38.8B39.8%39.1%54.4%
2024₩115.3B₩34.8B₩29.1B30.2%23.0%40.3%
2025₩156.8B₩51.7B₩35.2B33.0%22.4%38.0%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual revenue rose from KRW 81.5 billion in 2022 to KRW 156.8 billion in 2025, and operating profit rose from KRW 26.8 billion to KRW 51.7 billion over the same period. In 2025 revenue grew 36.1% and operating profit grew 48.6%, and the company called this its best result since its founding.

In 2024 revenue dipped 0.3% to KRW 115.3 billion and operating profit fell 24.4% to KRW 34.8 billion, with the operating margin falling to 30.2%. The operating margin peaked at 39.8% in 2023 and recovered to 33.0% in 2025.

Net income attributable to controlling shareholders was largest in 2023 at KRW 38.8 billion, fell to KRW 29.1 billion in 2024, and rose 21.0% to KRW 35.2 billion in 2025. At year-end 2025 total equity was KRW 157.4 billion and total liabilities were KRW 59.9 billion, a debt ratio of 38.0%.

Operating cash flow climbed from KRW 14.9 billion in 2024 to KRW 51.1 billion in 2025. Quarterly operating profit peaked in Q4 2025 at KRW 12.2 billion, then declined to KRW 11.2 billion in Q1 2026, KRW 11.1 billion in Q2 and KRW 5.51 billion in Q3.

In Q1 2026 revenue was KRW 40.2 billion and the gross margin reached 71.1%, up 6.9 percentage points, but selling and administrative expenses rose 83.8% and advertising costs rose 229.9%, which the company described as a temporary adjustment for mid-term investment.

Net income attributable to controlling shareholders was KRW 10.4 billion in Q1 and KRW 15.4 billion in Q2, both above operating profit, and the non-operating items behind that gap should be checked in the filed income statement.

Q3 posted a KRW 2.85 billion net loss, which the company tied to foreign currency translation losses. The sum of net income attributable to controlling shareholders over the last four quarters, from Q4 2025 to Q3 2026, is KRW 29.2 billion.

05

Industry analysis

The aesthetic medical device market moves with treatment demand and the pace at which overseas clinics adopt equipment. WON Tech has built a position in the domestic energy-based aesthetic device market, especially in noninvasive RF lifting equipment, and was credited for it by the Korea Exchange.

Company-released figures show demand widening across Asia, Europe, the Middle East and Latin America. In 2026 approval news came from Canada, Vietnam, Mexico and Taiwan, so country-by-country certification is a precondition for sales network expansion.

On competition, the company faces other device makers in domestic RF lifting and in overseas distribution, and its distinguishing feature is the consumable revenue that follows equipment placements.

Comparing sector-wide demand cycles and peer results would help separate whether overseas growth reflects a market recovery or the effect of the company's own subsidiary expansion. The company has said it will turn its overseas subsidiaries into regional planning and execution hubs to speed local decisions.

Aesthetic demand can be sensitive to economic conditions, and with an overseas share above 75% both exchange rates and local economies are variables. How these factors show up in Q3 results is the starting point for judging the sector backdrop.

06

Outlook

The company framed 2026 as the year it moves from a technology-focused manufacturer toward a global brand. It plans to launch several new products in sequence this year and to extend from aesthetic and medical devices into healthcare more broadly, managing development from planning to launch under a standard process.

Oligio equipment and its consumables are described as the stable revenue base as of Q1 2026. The overseas organization has been strengthened with new country heads in the United States and Japan and a new Southeast Asia command.

Higher selling and advertising costs were framed as mid-term investment, so whether those costs are absorbed by sales growth is the next thing to check. On financing, the board approved a KRW 75 billion unsecured private convertible bond in May 2026 for operating funds and debt repayment.

On shareholder returns, the board approved cancelling 1,153,767 treasury shares in November 2026, and a KRW 5 billion treasury share purchase trust contract was terminated in August 2026 after the purchases were completed.

Ahead of the Q1 2026 announcement, sell-side consensus projected revenue of KRW 47.9 billion and operating profit of KRW 15.9 billion, while actual Q1 revenue was KRW 40.2 billion and operating profit KRW 11.2 billion. Q3 2026 revenue of KRW 36.2 billion rose 9.0% year on year, but operating profit fell 27.6%.

The company announced on November 13, 2026 that cumulative revenue for January through September reached KRW 124.0 billion, up 12.2%.

07

Valuation

PER
10.9×
PBR
1.9×
ROE
18.2%
EPS
₩328
BPS
₩1,851
Dividend per share
₩50

Current multiples are best read alongside the earnings trend. Annual earnings rose sharply in 2025, but the company swung to a net loss attributable to controlling shareholders in Q3 2026, and the sum over the last four quarters is KRW 29.2 billion.

Earnings-based multiples therefore read differently depending on whether the 2025 annual result or the last four quarters is used as the base. Measured against year-end 2025 total equity of KRW 157.4 billion, the price-to-book ratio reflects a premium over net assets.

The debt ratio was 38.0% at year-end 2025, up from 29.3% in 2022 and 54.4% in 2023 before easing. If the convertible bonds convert into shares, the share count would increase and could affect per-share comparisons, so this should be considered alongside multiples. Shareholder returns have centered on treasury share purchases and cancellations rather than cash dividends.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Overseas growth and a rising export share

Cumulative overseas revenue for January through September 2026 rose 31.6%, lifting the overseas share of total revenue to 75.4%. According to company figures on a standalone basis, US revenue grew 117.8% and Thai revenue grew 44.2%.

The export share, which was 70.0% in 2025, extends a rise of roughly 10 percentage points from the prior year. Wider country approvals are also cited as expanding the markets where the company can sell.

Improving earnings structure and cash generation

The gross margin for Q1 2026 reached 71.1%, up 6.9 percentage points from 64.2% a year earlier. Consumable revenue following equipment placements is described as having become an established pattern. Operating cash flow rose to KRW 51.1 billion in 2025 from KRW 14.9 billion in 2024. The company said steady growth in high-margin consumable sales is supporting its cash flow.

Technology recognition and a shareholder return stance

The Korea Exchange named WON Tech a new 2026 KOSDAQ Rising Star, citing its technology centered on Oligio and its global growth potential. In November 2026 the board approved cancelling 1,153,767 treasury shares.

Treasury share purchase programs have continued through 2026, including a trust contract announced in July and later terminated after completion.

09

Bear factors

Operating profit down for three straight quarters

Operating profit peaked at KRW 12.2 billion in Q4 2025 and then fell to KRW 11.2 billion in Q1 2026, KRW 11.1 billion in Q2 and KRW 5.51 billion in Q3. Q3 operating profit was down 50.3% from the prior quarter and 27.6% from a year earlier.

In Q1 selling and administrative expenses rose 83.8% and advertising costs rose 229.9%. Investment costs growing faster than sales leave the timing of any margin recovery uncertain.

Swing to a parent net loss and earnings volatility

Net income attributable to controlling shareholders moved from KRW 10.4 billion in Q1 2026 and KRW 15.4 billion in Q2 to a KRW 2.85 billion net loss in Q3. The company said the foreign currency translation loss involves no cash outflow, yet the swing shows how sensitive reported profit is to exchange rates.

The gap between operating profit and net income changed quarter to quarter, so the quality of earnings needs checking in the filed statements.

Financing and a shortfall against consensus

On May 14, 2026 the board approved a KRW 75 billion unsecured private convertible bond. Ahead of the Q1 2026 results, sell-side consensus had projected revenue of KRW 47.9 billion and operating profit of KRW 15.9 billion, against actual figures of KRW 40.2 billion and KRW 11.2 billion.

If the convertible bonds convert, existing shareholders could be diluted, so the use of proceeds and conversion terms remain a weakness to monitor.

10

Risk factors

Exchange rates and translation gains or losses

With overseas sales at 75.4% of total, exchange rate moves feed directly into revenue and earnings. The company attributed the KRW 2.85 billion Q3 net loss mainly to foreign currency translation losses. The company has said such losses could reverse into gains if rates move, but quarterly earnings volatility remains.

Dependence on overseas approvals and local sales

Growth rests on approvals in key markets such as the US FDA and EU CE, so delays or distribution changes in a given country can affect results. Approvals in Canada, Vietnam, Mexico and Taiwan arrived in 2026, but timing and conditions differ by product and country. Whether the high growth rates in Thailand and the United States continue is also a point to monitor.

Upfront spending and funding needs

Selling, general and administrative expenses and advertising costs have grown sharply, pressuring margins until the effect of mid-term investment shows up in results. The KRW 75 billion convertible bond is aimed at operating funds and debt repayment, and conversion could dilute shareholders.

Treasury share cancellations signal a return policy, but they also require balancing cash use against funding needs.

11

What to watch next

  1. By end of December 2026

    Check whether the new products planned for this year, including Oligio XM, launch on schedule and contribute to fourth-quarter revenue and operating margin.

  2. End of March 2027 (statutory filing deadline)

    The 2026 annual report is the next periodic filing. It will confirm fourth-quarter and full-year results, the annual operating margin, the cost structure and the use of convertible bond proceeds.

  3. Around mid-May 2027

    This timing is an estimate based on Q1 2026 results being disclosed on May 13 and 14. Check whether revenue growth absorbs the higher selling and advertising costs, and whether net income attributable to controlling shareholders stays positive.

12

Overall view

WON Tech's disclosed results show revenue and operating profit reached their highest levels in 2025 after growing from 2022, with a 2025 operating margin of 33.0%. Overseas revenue rose to 75.4% of the total for January through September 2026, led by the United States and Thailand.

Quarterly operating profit, however, has declined for three straight quarters after peaking in Q4 2025, and Q3 2026 swung to a net loss attributable to controlling shareholders. The company frames higher selling and advertising costs as mid-term investment and says the foreign currency translation loss is non-cash.

Financing is moving alongside shareholder returns, with a KRW 75 billion convertible bond and treasury share cancellations, so use of proceeds and dilution need to be read together.

Strengths are overseas growth and a consumables-driven earnings base, while weaknesses are rising costs, exchange rate sensitivity and earnings volatility. The next confirmation point is the fourth-quarter and full-year results in the 2026 annual report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 16 more articles and sources
  1. rapportian.com
  2. news.nate.com
  3. news.nate.com
  4. m.news.nate.com
  5. news.nate.com
  6. news.nate.com
  7. news.nate.com
  8. sentv.co.kr
  9. medifonews.com
  10. kr.investing.com
  11. kr.investing.com
  12. fnnews.com
  13. bokuennews.com
  14. v.daum.net
  15. leadeconomy.co.kr
  16. v.daum.net

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis